Jonathan Krinsky, BTIG chief market technician, joins CNBC's Closing Bell to discuss market outlooks.

CEO of Simulations Plus, Shawn O’Connor, will participate in a panel discussion at the virtual BTIG Digital Health Forum on ...

Fintel reports that on November 19, 2024, BTIG upgraded their outlook for Aclaris Therapeutics (NasdaqGS:ACRS) from Neutral ...

BTIG Research began coverage on shares of VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) in a research report issued to clients and investors on Monday, MarketBeat.com reports. The brokerage set a ...

BTIG analyst Marvin Fong raised the firm’s price target on RealReal (REAL) to $5.50 from $4 and keeps a Buy rating on the shares. The firm ...

BTIG upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired full ex-China rights to an anti-TSLP humanized mAb and ...

Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...

Energy and Infrastructure Transition Analyst Lewis holds a virtual meeting with management on November 22 hosted by BTIG. Don't Miss out on Research Tools: Discover the latest stocks recommended by ...

Plug Power downgraded at BTIG Research, citing need for more product sales to boost margins in the hydrogen market.

NEW YORK--(BUSINESS WIRE)--BTIG announced today that its Digital Health Forum will take place on Monday, November 25, 2024. The event will be hosted by David Larsen, CFA, BTIG Healthcare IT and ...

Donald Trump has been somewhat cagey about his economic plans — especially tariffs — since voters elected him president. That ...

Donald Trump has been somewhat cagey about his economic plans — especially tariffs — since voters elected him president. That ...